Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 2,256 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1
Active & Responsive

A Mixed-Methods Metabolomics Investigation of Lifestyle and Energy Balance During Breast Cancer Survivorship

for
Breast Cancer
Location: Philadelphia PA
Sponsor: Abramson Cancer Center at Penn Medicine

Sex: Female

Age: 18+

Code: NCT07655934

Recruiting
Active & Responsive

Transcranial Magnetic Stimulation for Chemotherapy-Induced Peripheral Neuropathy in Breast and Gynecologic Cancer Survivors

for
Breast Cancer Female, Gynecologic Cancer
Location: Salt Lake City UT
Sponsor: University of Utah

Sex: Female

Age: 18+

Code: NCT07120100

Recruiting
Active & Responsive

A Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific ADC in Participants With Select Solid Tumors

for
Locally Advanced (Unresectable) or Metastatic Solid Tumors
Location: New York NY, Fairfax VA, Nashville TN, Houston TX,
Sponsor: NEOK Bio, Inc.

Sex: All

Age: 18+

Code: NCT07612176

Phase 1, Recruiting
Active & Responsive

ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy

for
Breast Cancer
Location: Richmond VA
Sponsor: Virginia Commonwealth University

Sex: Female

Age: 45 - 70+

Code: NCT06185205

Phase 2, Recruiting
Active & Responsive

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

for
Small-cell Lung Cancer, Neuroendocrine Carcinomas,
Location: New York NY, Philadelphia PA, Fairfax VA, Orlando FL,
Sponsor: IDEAYA Biosciences

Sex: All

Age: 18+

Code: NCT07174583

Phase 1, Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

Exploring the Feasibility of an Exercise and Noninvasive Brain Stimulation Intervention in Breast Cancer Survivors

for
Breast Cancer
Location: Boca Raton FL
Sponsor: Florida Atlantic University

Sex: All

Age: 18+

Code: NCT07587957

Recruiting
Active & Responsive

ARC101 in Advanced Solid Tumors

for
Advanced Solid Tumor
Location: Montreal, Toronto, Vancouver
Sponsor: Third Arc Bio

Sex: All

Age: 18+

Code: NCT06672185

Phase 1, Recruiting
Active & Responsive

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

for
Solid Tumor Malignancies, Colorectal Carcinoma,
Location: Philadelphia PA, Fairfax VA, Orlando FL,
Sponsor: Tasca Therapeutics

Sex: All

Age: 18+

Code: NCT07030257

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

for
Solid Tumor, Non-Small-Cell Lung Cancer,
Location: New York NY, Hackensack NJ, Fairfax VA, Buffalo NY,
Sponsor: Astellas Pharma Inc

Sex: All

Age: 18+

Code: NCT07094204

Phase 1, Recruiting
Active & Responsive

A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.

for
Metastatic Solid Tumors
Location: Nashville TN, Houston TX, Irving TX, San Antonio TX,
Sponsor: Erasca, Inc.

Sex: All

Age: 18 - 70+

Code: NCT07021898

Phase 1, Recruiting
Active & Responsive

A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

for
Solid Tumor Malignancies
Location: New Haven CT, Fairfax VA, Jacksonville FL, Sarasota FL,
Sponsor: Kumquat Biosciences Inc.

Sex: All

Age: 18+

Code: NCT06994806

Phase 1, Recruiting
Active & Responsive

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

for
Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm,
Location: Boston MA, New York NY, Toronto, Hamilton, Tampa FL,
Sponsor: Eli Lilly and Company

Sex: All

Age: 18+

Code: NCT07114601

Phase 1, Recruiting
Active & Responsive

Mayo Clinic Radiotherapy Patient Outcomes Registry and Biobanking Study

for
Solid Tumors, Hematologic Malignancies
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 0+

Code: NCT02457962

Recruiting
Active & Responsive

The Cancer Stage Shifting Initiative: Registry and Biorepository to Research and Address Health Disparities in Cancer Care

for
Cancer, Cancer Comorbidities
Location: Flint MI, Houston TX
Sponsor: National Minority Quality Forum

Sex: All

Age: 35+

Code: NCT07461493

Recruiting
Active & Responsive

Feasibility Study for the SIRA-1000, SIRA® RFA Electrosurgical Device as an Adjunct to Breast Conserving Surgery

for
Breast Cancer, Breast-conserving Surgery,
Location: Galveston TX
Sponsor: Innoblative Designs, Inc.

Sex: Female

Age: 50+

Code: NCT07206121

Recruiting
Active & Responsive

CREATE: Art for Children With Cancer

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Portland OR
Sponsor: OHSU Knight Cancer Institute

Sex: All

Age: 8 - 13

Code: NCT06342453

Recruiting
Active & Responsive

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

for
Breast Cancer
Location: Boston MA, Summit NJ
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT05950945

Phase 3, Recruiting
Active & Responsive

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

for
Solid Tumor
Location: Dallas TX, Scottsdale AZ, Portland OR, El Segundo CA,
Sponsor: Alyssum Therapeutics

Sex: All

Age: 18+

Code: NCT06234098

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

for
Metastatic Breast Cancer
Location: Durham NC, Columbus OH, Chattanooga TN, Nashville TN,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT03424005

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

for
Advanced Solid Tumors
Location: Moncton, Hackensack NJ, Fairfax VA, Kingston, Toronto,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT05067283

Phase 1, Recruiting

What is triple negative breast cancer?

Triple negative breast cancer, or TNBC, is breast cancer whose cells test negative for estrogen receptors, progesterone receptors, and excess HER2 protein, so hormone therapy and HER2 targeted drugs do not work against it. It tends to grow faster and is more common in women who have not gone through menopause, in Black women, and in people with an inherited BRCA1 mutation, so genetic testing is recommended for everyone diagnosed. In US data, five year relative survival is about 92 percent when it is found while localized, 67 percent with regional spread, and 15 percent once it has reached distant organs. Standard treatment for early stage disease is chemotherapy combined with immunotherapy before surgery, followed by more treatment after; metastatic disease is treated with chemotherapy, immunotherapy for PD-L1 positive tumors, and antibody drug conjugates. Other breast cancers are covered on our breast cancer clinical trials page.

Types of triple negative breast cancer clinical trials

Who can participate in triple negative breast cancer clinical trials?

Is triple negative breast cancer hereditary?

Stages of triple negative breast cancer, and why they matter for trials

How to enroll in a triple negative breast cancer clinical trial